Does Rallies show Form 4 insider transactions for IMA?

Yes. Rallies tracks IMA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is IMA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IMA. It does not provide personalized investment advice.

IMA (ImageneBio, Inc. Common Stock) Stock Analysis - Insider Trades

ImageneBio, Inc. Common Stock (IMA) is a publicly traded Healthcare sector company. As of May 21, 2026, IMA trades at $5.41 with a market cap of $63.73M and a P/E ratio of -0.56. IMA moved +0.00% today. Year to date, IMA is -15.60%; over the trailing twelve months it is flat. Its 52-week range spans $3.94 to $18.00. Analyst consensus is buy with an average price target of $13.00. Rallies surfaces IMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading IMA stock inside the company?

Recent IMA insider activity includes SLATTERY JOSEPH P bought 16.00K, Bonita David P bought 83.61K, Stampacchia Otello bought 267.56K, HEMPEL PAUL T sold 100, and HEMPEL PAUL T sold 745. Rallies tracks insider transaction dates, shares, prices, and estimated values.

IMA Key Metrics

Key financial metrics for IMA
Metric	Value
Price	$5.41
Market Cap	$63.73M
P/E Ratio	-0.56
EPS	$-9.64
Dividend Yield	0.00%
52-Week High	$18.00
52-Week Low	$3.94
Volume	0
Avg Volume	0
Revenue (TTM)	$800.00K
Net Income	$-45.35M
Gross Margin	0.00%

Recent IMA Insider Trades

SLATTERY JOSEPH P bought 16.00K (~$95.84K) on Dec 24, 2025.
Bonita David P bought 83.61K (~$2.50M) on Jul 25, 2025.
Stampacchia Otello bought 267.56K (~$8.00M) on Jul 25, 2025.
HEMPEL PAUL T sold 100 (~$3.70K) on May 17, 2010.
HEMPEL PAUL T sold 745 (~$27.59K) on May 17, 2010.

Latest IMA News

ImageneBio Raises $30M to Advance IMG-007 Trials in Alopecia Areata and Atopic Dermatitis — Apr 13, 2026
ImageneBio expands IMG-007 dosing regimens after March safety review, targets 2027 readout — Mar 10, 2026
ImageneBio Appoints CMO to Expand Phase 2b ADAPTIVE Trial to UK and Europe — Feb 10, 2026

IMA Analyst Consensus

3 analysts cover IMA: 0 strong buy, 2 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $13.00.

Common questions about IMA

Who is trading IMA stock inside the company?: Recent IMA insider activity includes SLATTERY JOSEPH P bought 16.00K, Bonita David P bought 83.61K, Stampacchia Otello bought 267.56K, HEMPEL PAUL T sold 100, and HEMPEL PAUL T sold 745. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for IMA?: Yes. Rallies tracks IMA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is IMA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IMA. It does not provide personalized investment advice.